Tag: Nusinersen

  • Study on the treatment of people with 5q-SMA with nusinersen in adulthood

    Study on the treatment of people with 5q-SMA with nusinersen in adulthood

    —

    Treatment with the drug nusinersen is available for people with 5q-associated spinal muscular atrophy (5q-SMA). In our application study with people with 5q-SMA who received nusinersen therapy in adulthood, the treatment goals, symptom progression and treatment satisfaction with the drug were systematically investigated. In the period from July 2019 to September 2020, Ambulanzpartner conducted an…

  • Nusinersen application study successfully started in people with SMA in adulthood

    Nusinersen application study successfully started in people with SMA in adulthood

    —

    The nusinersen application study is a nationwide, systematic patient survey of 100 patients with spinal muscular atrophy (SMA), in which important findings on the efficacy of nusinersen in adulthood are gained. The drug Nusinersen The drug nusinersen (trade name Spinraza) was approved for the treatment of SMA in Europe in 2017 on the basis of…

  • Study to record treatment with nusinersen in adults

    Study to record treatment with nusinersen in adults

    —

    Nusinersen (Spinraza®) is approved for the treatment of 5q-associated spinal muscular atrophy (SMA). For infants and children, nusinersen can halt the progression of the disease and improve muscle function. For adults, no systematic data on treatment with nusinersen are available to date. Scientific treatment documentation is therefore necessary to improve the data situation for adults…